Page 2 - Quick Inventory News Today

Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this podcast, twice a month, we cover the latest in healthcare news and research evidence. Our episode is live! Episode Description We begin this episode by discussing our article of the week from the New England

1. In this randomized controlled trial, ketamine was noninferior to electroconvulsive therapy (ECT) for reducing symptoms of treatment-resistant major depression (TRMD). 2. ECT was associated with temporarily decreased memory recall and musculoskeletal adverse effects, while ketamine was associated with dissociation. Evidence Rating Level: 1 (Excellent) Study Rundown: Major depressive disorder is a leading cause of

The results show 55.4% of patients in the ketamine group had a response, compared to 41.2% of patients in the ECT group.

For patients with treatment-resistant major depression without psychosis, ketamine is noninferior to electroconvulsive therapy.

For patients with treatment-resistant major depression without psychosis, ketamine is noninferior to electroconvulsive therapy.

WEDNESDAY, May 31, 2023 (HealthDay News) -- For patients with treatment-resistant major depression without psychosis, ketamine is noninferior to electroconvulsive therapy (ECT), according to a study published online May 24

ECT is the gold standard for treatment-resistant depression, but a new head-to-head trial suggests ketamine is at least as effective, and with fewer side effects.

There is no difference in the efficacy of IV ketamine and its intranasal counterpart for treatment-resistant depression, but cost and the speed of effect may be the factors that determine treatment choice.

New prospective data show more adult patients achieved clinical response with ketamine than the historic standard ECT over a 6-month regimen.

Based on the study results, investigators concluded that there is justification for a randomized clinical trial.